CKD Bio

CKD Bio EBIT per Employee

EBIT per Employee of CKD Bio (063160.KS) as of Oct 19, 2026.

EBIT per Employee

-KRW

Last updated:

EBIT per Employee of CKD Bio is 2026 - KRW. EBIT per Employee of CKD Bio was 2025 - KRW. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CKD Bio Stock analysis

What does CKD Bio do? CKD Bio Corp, headquartered in Seoul, South Korea, operates in the Health Care sector, specializing in pharmaceuticals. The company develops and manufactures active pharmaceutical ingredients, including antibiotic components like DMCTs and rifampicins, immunosuppressive agents such as cyclosporin and tacrolimus, and diabetes remedies like acarbose. Products are distributed domestically and internationally across markets in America, China, Europe, Africa, Southeast Asia, Latin America, and the Middle East. Listed on 11 December 2001. CKD Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CKD Bio stock

On Eulerpool you can find the complete historical development of EBIT per Employee CKD Bio since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's CKD Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — CKD Bio

All Key Metrics — CKD Bio